(Adds analyst comment, background and profit figures) May 1 (Reuters) - Consumer healthcare company Haleon reported first-quarter revenue slightly below market estimates on Wednesday, as volumes declined due to retailer destocking in U.S. and cooling demand for some of its medicines after a surge last year. The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth. Revenues stood at 2.92 billion pounds ($3.64 billion) for the quarter ended March 31, slightly missing expectations of 2.93 billion pounds, according to a company-compiled consensus. On a reported basis, revenue was down 2.2% on last year. "The miss in volumes more than offsets a (played down) margin beat, outlook no change. We could expect the stock to be an under performer this AM," Jefferies analysts said. Shares in the FTSE 100 group fell 1.8% to 333.30 pence, to become one of the top losers on the blue-chip index. The stock has risen about 5% this year as of Tuesday's close. Haleon, whose name is inspired by the merging 'Hale', which is an old English word that means 'in good health', and Leon which is associated with the word 'strength'. It comprises assets from GSK and Pfizer and sells non-prescription drugs, vitamins and oral care products. It was spun-off from GSK in 2022. Demand for its oral health products and multivitamins held steady during the reported quarter, and the company re-affirmed its full-year outlook outlined in February. Adjusted operating profit grew 2.3% to 707 million pounds in the first quarter. On Tuesday, the firm disclosed plans to shut its UK production site which makes Sensodyne toothpastes by 2026, saying it was not longer viable to manufacture its products there. ($1 = 0.8021 pounds) (Reporting by Eva Mathews and Chandini Monnappa in Bengaluru; Editing by Rashmi Aich and Michael Perry)
UPDATE 2-Sensodyne-maker Haleon posts tepid sales as demand for some products cool off
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...